BRII-179

Phase 2

Vir Biotechnology, Inc. (VIR)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

VIRPhase 2$1.9B

BRII-179 Phase 2 Est. Readout

BRII-179• For Treatment of Chronic Hepatitis B Virus Infection150

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in For Treatment of Chronic Hepatitis B Virus Infection

View Full Landscape

Drug Information

Target Indication

For Treatment of Chronic Hepatitis B Virus Infection

Clinical Trial

NCT06491563

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VIR

Vir Biotechnology, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

BulevirtidePhase 3

Viral Hepatitis

TobevibartPhase 3

Viral Hepatitis

VIR-7831 (sotrovimab)Phase 3

Covid19

ElebsiranPhase 3

Viral Hepatitis

NRTIPhase 2

Hepatitis D, Chronic

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts